糖心Vlog

Scientists at 糖心Vlog are part of breakthrough research which has uncovered a new cell therapy approach that boosts immune cell activity in malignant tumours.

The discovery will significantly enhance the immune system鈥檚 effectiveness in eliminating cancer cells.

Over the past few years, an exciting new era in cancer immunotherapy has emerged with the advent of immune checkpoint blockade (ICB) therapy which overrides the immune system鈥檚 built-in 鈥渃heckpoints鈥� or brakes that prevent excessive immune activation and damage to healthy tissues.

Tumours outsmart the immune cells by engaging these breaks so they are not able to do their job, but ICB therapy reactivates the immune system so it is able to engage and kill the tumour cells.

However, despite these exciting discoveries only a fraction of patients respond to these therapies and some develop adverse side effects of the drugs as they also damage healthy cells. A better understanding and discovery of new targets is essential to expand this treatment to help a wider range of patients.

Funded by the and published in top journal , this latest research has identified a new protein 鈥漜heckpoint鈥� within immune T-cells 鈥� known a Rasal1. This finding will inform future drug design to target this protein so it does not inhibit the immune system penetrating and attack tumours.

The international research project involved Dr Youg Raj Thaker, for our School of Life Sciences, working with scientists in Cambridge, Canada and Germany.

Dr Raj Thaker said: 鈥淚mmune checkpoint blockade therapy has shown great promise in cancer treatment, however, only some cancer types respond to these therapies. By identifying this new T-cell protein we can target a wider range of tumours using combination therapy approaches.鈥�

Dr Christopher Rudd, from the Universit茅 de Montr茅al, added: 鈥淭his discovery demonstrates that modulation of the identified protein can activate the immune system and lead to destruction of the cancer cells.鈥�